-
公开(公告)号:US20100048539A1
公开(公告)日:2010-02-25
申请号:US12513498
申请日:2007-11-02
申请人: Donatella Chianelli , Xiaolin Li , Xiaodong Liu , Jon Loren , Valentina Molteni , Juliet Nabakka , Laszlo Revesz , Lawrence B. Perez , Clinton Brooks , Wojciech Wrona , Paul William Manley , Werner Breitenstein
发明人: Donatella Chianelli , Xiaolin Li , Xiaodong Liu , Jon Loren , Valentina Molteni , Juliet Nabakka , Laszlo Revesz , Lawrence B. Perez , Clinton Brooks , Wojciech Wrona , Paul William Manley , Werner Breitenstein
IPC分类号: A61K31/506 , C07D401/14 , C07D413/14 , C07D405/14 , A61K31/5377 , A61K31/538 , A61K31/55 , C12N5/00 , A61P35/00 , A61P37/00 , A61P3/00 , A61P25/00 , A61P9/00 , A61P37/08
CPC分类号: C07D401/14 , C07D401/04 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
摘要: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to beat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFRα and PDGFRβ kinases. Formula (I).
摘要翻译: 本发明提供了一类新颖的化合物,包含这些化合物的药物组合物和使用这些化合物来击败或预防与异常或失调的激酶活性相关的疾病或病症的方法,特别是涉及c-kit,PDGFRα异常活化的疾病或病症,以及 PDGFR&bgr 激酶。 式(I)。